Eribulin in advanced breast cancer: safety, efficacy and new perspectives

被引：9
|
作者：
Garrone, Ornella [1 ]
Miraglio, Emanuela [1 ]
Vandone, Anna Maria [1 ]
Vanella, Paola [1 ]
Lingua, Daniele [1 ]
Merlano, Marco C. [1 ]
机构：
[1] Med Oncol AOS Croce & Carle Osped Insegnamento, Cuneo, Italy
来源：
FUTURE ONCOLOGY | 2017年 / 13卷 / 30期
关键词：
chemotherapy; eribulin; mechanism of action; metastatic breast cancer; new treatment; HALICHONDRIN-B ANALOG; ADVANCED SOLID TUMORS; PHASE-I; LOCALLY RECURRENT; 1ST-LINE THERAPY; CONSORTIUM TRIAL; DOSE-ESCALATION; POOLED ANALYSIS; MESYLATE E7389; CHEMOTHERAPY;
D O I：
10.2217/fon-2017-0283
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Eribulin is a synthetic analog of halichondrin B belonging to microtubule-targeted agents with a distinct mechanism of inhibition of microtubule dynamics. This molecule has multiple nonmitotic effects on tumor biology, exhibiting effects on epithelial-mesenchimal transition and tumor vasculature. We review here preclinical and clinical studies on eribulin. The mitotic and nonmitotic effects together with its favorable safety profile make eribulin a unique drug with high potential in the treatment of metastatic breast cancer. The new emphasis of eribulin mechanism of action on vascular remodeling, microenvironment modifications and reversal of epithelial-mesenchimal transition paves the way to rethinking the use of the drug in an immunological perspective.
引用
收藏
页码：2759 / 2769
页数：11
相关论文
共 50 条
  • [41] Multicentric retrospective study on the treatment characteristics, efficacy and safety of eribulin in Slovenian patients with breast cancer.
    Dobovisek, Luka
    Borstnar, Simona
    Ravnik, Maja
    Privsek, Nina
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [42] Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
    Ni, M.
    Zhou, L.
    Lu, Y.
    Zhang, L.
    Li, X.
    Chen, M.
    Yang, A.
    Zhang, L.
    Xu, F.
    Yuan, Z.
    Wang, S.
    Shi, Y.
    An, X.
    ANNALS OF ONCOLOGY, 2023, 34 : S1490 - S1490
  • [43] Efficacy and safety of eribulin in patients with metastatic breast cancer in early and late application: real life experience
    Filonenko, D.
    Gorbunova, V.
    Manzyuk, L.
    Kovalenko, E.
    Zhukova, L.
    Bolotina, L.
    Kolyadina, I.
    Manikhas, A.
    Zhilyaeva, L.
    Karabina, E.
    BREAST, 2019, 44 : S63 - S64
  • [44] Eribulin for advanced breast cancer: Clinical experience in the real world
    Walshaw, Richard C.
    Shaukat, Shazril
    Chan, Kevin
    Armstrong, Anne Caroline
    Howell, Sacha Jon
    Wardley, Andrew M.
    Wilson, Gregory
    Loncaster, Juliet
    Magee, Brian
    Bhatt, Lubna
    Chittalia, Abbas
    Lander, Helen
    Tetlow, Christine
    Misra, Vivek
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [45] Comment on the work Eribulin in the treatment of patients with advanced breast cancer
    Krzakowski, Maciej
    ONCOLOGY IN CLINICAL PRACTICE, 2013, 9 (01): : 15 - 15
  • [46] EFFICACY AND TOXICITY OF ERIBULIN IN REAL-LIFE NON-SELECTED ADVANCED BREAST CANCER PATIENTS
    Brems-Eskildsen, Anne Sofie
    Kristoffersen, Kristina Bak
    Linnet, Soeren
    Lorincz, Tamas
    Langkjer, Sven Tyge
    BREAST, 2017, 36 : S52 - S53
  • [47] Comparative efficacy and safety of eribulin versus paclitaxel in breast cancer: a systematic review and meta-analysis
    Zhang, Jialin
    Su, Jingyang
    Ni, Cui
    Lu, Jinhua
    FUTURE ONCOLOGY, 2024, 20 (40) : 3507 - 3517
  • [48] A retrospective safety and efficacy analysis of the first patients treated with eribulin for metastatic breast cancer in Stockholm, Sweden
    Kessler, Luisa
    Falato, Claudette
    Margolin, Sara
    Bergh, Jonas
    Foukakis, Theodoros
    ACTA ONCOLOGICA, 2015, 54 (04) : 522 - 529
  • [49] Efficacy and safety of eribulin in patients with triple negative metastatic breast cancer: Real life experience.
    Manikhas, Alexey
    Kovalenko, Elena
    Manzyuk, Valentina
    Bolotina, Larisa V.
    Zhilyaeva, Larisa
    Karabina, Elena
    Ponomarenko, Dmitry
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [50] The relative effectiveness of eribulin for advanced breast cancer treatment: a study of the southeast Netherlands advanced breast cancer registry
    Pouwels, X. G. L. V.
    Geurts, S. M. E.
    Ramaekers, B. L. T.
    Erdkamp, F.
    Vriens, B. E. P. J.
    Aaldering, K. N. A.
    van de Wouw, A. J.
    Dercksen, M. W.
    Smilde, T. J.
    Peters, N. A. J. B.
    van Riel, J. M.
    Pepels, M. J.
    Heijnen-Mommers, J.
    Joore, M. A.
    Tjan-Heijnen, V. C. G.
    de Boer, M.
    ACTA ONCOLOGICA, 2020, 59 (01) : 82 - 89
12345